惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Spread Privacy
Spread Privacy
P
Palo Alto Networks Blog
P
Proofpoint News Feed
AI
AI
Help Net Security
Help Net Security
S
Securelist
T
Troy Hunt's Blog
K
KPMG report finds enterprise disconnect between AI and its ROI | CIO
C
Cisco Blogs
Scott Helme
Scott Helme
Hacker News - Newest:
Hacker News - Newest: "LLM"
Vercel News
Vercel News
Exploit-DB.com RSS Feed
Exploit-DB.com RSS Feed
CTFtime.org: upcoming CTF events
CTFtime.org: upcoming CTF events
B
Blog
GbyAI
GbyAI
Recent Commits to openclaw:main
Recent Commits to openclaw:main
D
Darknet – Hacking Tools, Hacker News & Cyber Security
P
Proofpoint News Feed
S
Security Affairs
Cisco Talos Blog
Cisco Talos Blog
AWS News Blog
AWS News Blog
T
Tenable Blog
H
Help Net Security
NISL@THU
NISL@THU
F
Fortinet All Blogs
博客园_首页
G
GRAHAM CLULEY
L
LINUX DO - 最新话题
P
Privacy International News Feed
G
Google Developers Blog
博客园 - Franky
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
cs.CL updates on arXiv.org
cs.CL updates on arXiv.org
Security Archives - TechRepublic
Security Archives - TechRepublic
The Register - Security
The Register - Security
L
LangChain Blog
aimingoo的专栏
aimingoo的专栏
T
Tor Project blog
P
Privacy & Cybersecurity Law Blog
量子位
C
Cyber Attacks, Cyber Crime and Cyber Security
Forbes - Security
Forbes - Security
S
Secure Thoughts
Simon Willison's Weblog
Simon Willison's Weblog
D
Docker
Recorded Future
Recorded Future
博客园 - 三生石上(FineUI控件)
L
Lohrmann on Cybersecurity
T
Tailwind CSS Blog

Latest Business Laws, Legal Insights, News & Updates | The HinduBusinessLine

Corporations have a fundamental duty to protect ecosystem: SC holds How to copyright colours Only strong reforms can clear massive backlog of court cases SC reasserts ‘bail is the rule’ doctrine in landmark ruling Misleading ads: How global brands are testing India’s regulatory framework How the Supreme Court verdict is set to reshape India’s mining industry Income Tax tribunal paves way for double deduction claims Where does the liability of the principal borrower begin and end? Why fixed-dose combination drugs need a tighter leash Who is a ‘workman’? SC reiterates binding nature of government tenders Corporate guarantee: A ‘yearly’ quandary A treaty to protect traditional knowledge IBBI’s proposed ‘guarantees’ under fire Guidelines diminish arbitration’s role in government procurement disputes Tooth-and-nail fight over trademark colours RBI expands overseas portfolio investment options Balancing business revival and creditor interests under IBC: A statistical insight Upholding tenets of fairness in arbitration ‘Conscious acceptance’ necessary for arbitration agreements AI under new management: EU sets global standard with Artificial Intelligence Act DMRC vs DAMEPL: A legal rollercoaster culminates as SC presents ‘cure’ Indian innovators rally behind Digital Competition Bill New CCI regulations: Tightening the reins on confidential information Amending nuclear law to spur ‘pink’ hydrogen generation Level up or Log out: India’s gaming industry at a crossroads Blurred boundaries: Taxing escrowed funds in M&A deals No consideration, no tax When insolvency meets money laundering Strengthening whistleblowers’ hands Electoral bonds case: Transparency triumphs over donors’ right to privacy Arbitration trumps criminality Vedanta’s environmental violations: A wake-up call for industries Mediation, the future of insolvency resolution? Interpreting Sec 29A(c) of IBC: NCLAT shows how No liability for directors who resigned before cheque issue, rules SC How to save deals from falling apart Madras High Court backs taxpayer in GST delayed payments interest case The promise of voluntary carbon market Are compulsorily convertible debentures debt or equity? Navigating the pre-arbitration maze Making deepfakes work Dissenting creditor’s settlement issue sent to larger bench The permanence of skill in the arena of monetary play SC solves the stamp duty puzzle in arbitration Nomination is not a statutory testament, says Supreme Court in landmark verdict The EU’s AI Act and the Brussels effect Apex court rules in favour of Jindal Steel RBI rules for cybersecurity in financial institutions Non-signatories join the arbitration bandwagon Ramakrishna Forgings wins at SC, set to bag ACIL Is women’s reservation merely a paper tiger? SC gives confidence boost to creditors in landmark verdict Revolutionising real estate insolvency with enhanced protections for homebuyers Property redevelopment approvals: Lessons from Bombay HC M Sricharan RangaRajan’s ‘Treatise on Arbitration’ provides a detailed insight on arbitration CCI’s new merger norms: Hits and misses Streamlining civil litigation: Supreme Court’s comprehensive guidelines Demat mandated for private companies too
Trademark issues in naming drugs
By Team Gavel · 2023-12-31 · via Latest Business Laws, Legal Insights, News & Updates | The HinduBusinessLine

Do IMOX and INIMOX sound so similar to you that you will be confused over which to ask for when you stand at the pharmacy counter?

IMOX is a brand that belongs to IPCA Laboratories Pvt Ltd; INIMOX is of Indian Immunologicals Ltd. IPCA objected (successfully) to INIMOX to the Registrar of Trade Marks Registry. A legal dispute ensued, which was settled by the Madras High Court last month.

The Court ruled in favor of Indian Immunologicals Ltd, noting that there were key differences between the two drugs. IMOX is a tablet for humans; INIMOX an injection for animals. Case closed.

Indian Immunologicals Ltd offered several legal precedents of similar-sounding names where no relief was granted to the objecting party. Some of them are: Stimuliv (Corona Remedies) and Stimu-let (Franco-Indian Pharmaceuticals), Meto (Orchid Chemicals) and Metox (Wockhardt), Zincovit (Apex Laboratories) and Zinconia (Zuventus Health Care), Meronem (Astrazeneca) and Meromer (Orchid Chemicals), Netromycin (Schering Corporation) and Netmicin (United Biotech).

However, there is a larger issue underlying the dispute. The names of most of the drugs sold in the market are derived from their underlying ‘active pharmaceutical ingredient’. Therefore, when rival companies name their drugs, the names are bound to be somewhat similar. How do you register their names?

The Madras High Court judgment lays down certain principles, which have been analysed by Vindhya Mani, Mohit Kar and Kriti Sood, lawyers at the law firm Lakshmikumaran & Sridharan, in an article in Mondaq. They note: “The Court concluded that marks that are derived from API or generic names are weaker in comparison to arbitrary or coined marks. The Court held that the larger the portion of the API or disease name that a mark uses, the weaker is its protection. Similarly, if a mark contains additional terms and unique elements apart from what it has borrowed from an API or disease name, then its protection would be stronger. This apart, the Court maintained that the analysis of “visual, phonetic and structural” similarity will play an important role in deciding the outcome of infringement, passing off, or proceedings involving strength of marks.”

Published on December 31, 2023